Autoimmune Neurology Testing - Mayo Clinic Laboratories
Recognized as a world leader in the diagnosis and treatment of autoimmune neurologic disorders, Mayo Clinic mounts unmatched resources for developing new diagnostic biomarkers and unique laboratory tests.
Mayo Clinic Laboratories: Quality testing from start to finish - Insights
Guided by a patient-centric philosophy, Mayo Clinic Laboratories has a unique internal structure of quality specialists, coordinators, and engineers who constantly evaluate and improve laboratory operations. This structure supports a host...
Clinical microbiology at Mayo Clinic: A look back and ahead - Insights
The field of clinical microbiology has a long and distinguished history at Mayo Clinic. Since the early 1900s, the clinical microbiology team has played important and leading roles in advancing testing and patient care.
Check out the second episode of “Life of a Specimen,” a video exploration of the complex path taken by patient samples through testing at Mayo Clinic Laboratories. In this episode, we hear about the quality processes and careful treatment...
Antibody Prevalence in Epilepsy and Encephalopathy (APE2) Score - Insights
In this month’s “Hot Topic,” Divyanshu Dubey, M.B.B.S., discusses how patients with encephalopathy and/or epilepsy of unknown etiology may have an autoimmune or paraneoplastic cause.
Platelet Transmission Electron Microscopy and Flow Cytometry - Insights
In this "Hot Topic," Dong Chen, M.D., Ph.D., describes how flow cytometry, electron micrographic study, and molecular testing are used to diagnose platelet function disorders.
Antibody Prevalence in Epilepsy and Encephalopathy (APE2) Score - Insights
In this month’s “Hot Topic,” Divyanshu Dubey, M.B.B.S., discusses how patients with encephalopathy and/or epilepsy of unknown etiology may have an autoimmune or paraneoplastic cause.
A recent Mayo Clinic study has found that many U.S. health care providers are habitually ordering a mostly unnecessary, and quite expensive, genetic test to identify a patient’s hereditary risk of venous thromboembolism.
Detection of (1→3)-𝝱-D-glucan as a Marker of Invasive Fungal Disease - Insights
In this month’s “Hot Topic,” Elitza Theel, Ph.D., will discuss the detection of (1→3)-β-D-glucan (BDG) in serum as a biomarker for the presence of invasive fungal infections.
Find out how our suite of MayoComplete next-generation sequencing panels puts patients on the right treatment path.